EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States

Reema Mody iD, Karishma Desai iD, Chia-Chen Teng, Gally Reznor, Grace Stockbower, Michael Grabner iD, Brian D Benneyworth

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16372 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Reema Mody und 6 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Weight Loss, Glycemic Control, Hypoglycemic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims The goal of this observational, single‐cohort, pre‐post study was to describe the association of tirzepatide with glycaemic control and weight loss in patients with type 2 diabetes (T2D) in a US commercially insured population. Materials and Methods Using the Healthcare Integrated Research Database (HIRD®), members ≥18 years, diagnosed with T2D, initiating tirzepatide between 13 May 2022 and 31 January 2023, with ≥1 glycated haemoglobin (HbA1c) result around the index date and the end of the 6‐month follow‐up period were identified. Baseline demographics and antihyperglycaemic medication use and key outcomes (HbA1c and weight) at 6‐month follow‐up were assessed overall and in subgroups stratified by baseline glucagon‐like peptide‐1 (GLP‐1) receptor agonist (RA) use and HbA1c (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Weight LossGlycemic ControlHypoglycemic AgentsTirzepatideHumansFemaleMaleMiddle AgedUnited StatesGlycated HemoglobinAdultAgedBlood GlucoseCohort StudiesGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

GIPGLP‐1effectivenessobservational studyreal‐world evidencetype 2 diabetes

Substanzen

Hypoglycemic AgentsGlycated HemoglobinTirzepatideBlood GlucoseGlucagon-Like Peptide-1 Receptor Agonistshemoglobin A1c protein, human

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Carelon Research, Wilmington, Delaware, USA.

ORCID-Profile: Reema Mody, Karishma Desai, Michael Grabner

Förderung

  • Eli Lilly and Company

Zitieren

APA

Mody, R., Desai, K., Teng, C. C., Reznor, G., Stockbower, G., Grabner, M., & Benneyworth, B. D. (2025). Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16372

Vancouver

Mody R, Desai K, Teng CC, Reznor G, Stockbower G, Grabner M, et al. Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16372

BibTeX
@article{Mody2025,
  author = {Mody, Reema and Desai, Karishma and Teng, Chia-Chen and Reznor, Gally and Stockbower, Grace and Grabner, Michael and Benneyworth, Brian D},
  title = {Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16372}
}
Kostenlos starten →